Single-Center 8-Years Clinical Follow-Up of Cladribine-Treated Patients From Phase 2 and 3 Trials

Background: Cladribine is approved for the treatment of highly-active relapsing multiple sclerosis (MS), where it is also effective on disability progression. In the present single-center study, we aim to report on the 8-years clinical follow-up of 27 patients included in phase 2 and 3 clinical tria...

Descripción completa

Detalles Bibliográficos
Autores principales: Moccia, Marcello, Lanzillo, Roberta, Petruzzo, Martina, Nozzolillo, Agostino, De Angelis, Marcello, Carotenuto, Antonio, Palladino, Raffaele, Brescia Morra, Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311570/
https://www.ncbi.nlm.nih.gov/pubmed/32625161
http://dx.doi.org/10.3389/fneur.2020.00489

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311570/
https://www.ncbi.nlm.nih.gov/pubmed/32625161
http://dx.doi.org/10.3389/fneur.2020.00489

Ejemplares similares